|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We analyzed T1-weighted, gadolinium-enhanced MR images of a retrospective cohort of 647 primary glioblastoma patients diagnosed between 2005-2013, and performed a multivariable Cox regression analysis to adjust the prognostic effect of SVZ involvement for clinical patient- and tumor-related factors.Protein expression patterns of a.o. markers of neural stem cellness (CD133 and GFAP-δ) and (epithelial-) mesenchymal transition (NF-κB, C/EBP-β and STAT3) were determined with immunohistochemistry on tissue microarrays containing 220 of the tumors.
|
31603915 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CCAAT enhancer binding protein β promotes tumor growth and inhibits apoptosis in prostate cancer by methylating estrogen receptor β.
|
29322786 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For in vivo antitumor studies, the tumor growth rate of mice treated with DTX-loaded <sup>D</sup>T7-LIP was significantly inhibited compared to that in mice treated with DTX-loaded <sup>L</sup>T7-LIP and DTX-loaded Tf-LIP.
|
30395963 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Second, C/EBP-β LIP down-regulated Pgp and up-regulated calreticulin that triggered the dendritic cell (DC)-mediated phagocytosis of tumor cell, followed by the activation of anti-tumor CD8<sup>+</sup>T-lymphocytes upon doxorubicin treatment.
|
30482226 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, CaMKKβ-AMPKα2 signaling constitutes a key tumor suppressor pathway that activates a novel UPA-cancelling mechanism to unmask the cytostatic and pro-senescence functions of C/EBPβ.
|
29563610 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, when SW-480 cells were co-transfected with C/EBPβ, or pretreatment with TNFα, Rg3 failed to inhibit tumor growth.
|
29169725 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CEBPB copy number gain in Ewing sarcoma was previously shown to be associated with worse clinical outcome compared to tumors with normal CEBPB copy number, although the mechanism was not characterized.
|
28148901 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RUNX1t1 is a C/EBPβ-associated tumor suppressor.
|
27522676 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The transcription factor (TF) CCAAT/enhancer binding protein beta (CEBPB) is important for maintaining the tumor initiating capacity and invasion ability.
|
27716259 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Next, the HUVEC tube formation assay, Western blot, qPCR, RNA silencing, chromatin immunoprecipitation, luciferase reporter and ELISA assays were performed to examine the role of IL-6 and C/EBPβ in the formation of the angiogenic microenvironment in EGFRvIII-positive tumors.
|
25382637 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that loss of CCAAT-enhancer binding protein beta (C/EBPβ), a differentiation factor for the mammary epithelium, was associated with signs of EMT in triple-negative human breast cancer, and in invasive areas of mammary tumors in MMTV-PyMT mice.
|
23955085 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these facts suggest that the tumor suppression in SMMC-7721 by C/EBPβ 3'UTR RNA is due to the inhibition of protein kinase Cε activity through direct physical interaction between C/EBPβ 3'UTR RNA and protein kinase Cε.
|
21283634 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, we show that HER2-overexpressing breast cancer cells avert TGFβ- and OIS-mediated tumor suppression by switching expression of 2 functionally distinct isoforms of the transcription factor C/EBPβ, which has been implicated previously in breast cancer development.
|
21098707 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
One of the four genes in the prognostic signature, CCAAT/enhancer binding protein beta (C/EBPB), is expressed at higher levels in both primary relapsing tumors and metastatic tumors than in primary nonrelapsing tumors.
|
15805255 |
2005 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The expression level of the C/EBP alpha and C/EBP beta genes were examined between tumor and non-tumorous tissues of the same hepatocellular carcinoma patients with quantitative real-time polymerase chain reactions.
|
12680236 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transfection of cDNA in 3'untranslated region of human nuclear factor for interleukin-6 (NF-IL6 3'UTR) induced tumor suppression in a human hepatoma cell line. cDNA array analysis was used to reveal changes in gene expression profile leading to tumor suppression The results indicate that this suppression was not due to activation of dsRNA-dependent protein kinase, nor to inactivation of oncogenes; rather, all the changes in expression of known genes, induced by NF-IL6 3'UTR cDNA may be ascribed to the suppression of cellular malignancy.
|
14728809 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although the inter-patient variability was large, we found that LIP, the isoform of C/EBPbeta known to inhibit transcription, was expressed at higher levels in Duke's stage B tumors compared with Duke's stage A, whereas Duke's C tumors had the lowest LIP expression.
|
10760820 |
2000 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A translationally regulated, dominant-negative isoform of CCAAT/enhancer-binding protein beta is expressed in transplantable and primary mouse mammary tumors of different etiologies but is not expressed in preneoplastic mammary hyperplasias or in primary prostate, lung, lens, ovary or lymphoid tumors.
|
8813130 |
1996 |